Cited by 193Cardiac electrophysiology and arrhythmiasCardiac Arrhythmias and TreatmentsPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide

Open access

Fish, Frank A, Gillette, Paul C, Benson, D.Woodrow·1991·Journal of the American College of Cardiology

DOI 10.1016/0735-1097(91)90586-x

Open this paper in CoChat — free account Open PDF

Abstract

The potential for proarrhythmic responses to the class IC sodium channel-blocking drugs encainide and flecainide has not been well described in young patients. Therefore, data were retrospectively collected from 36 institutions regarding 579 young patients who were administered encainide or flecainide for treatment of supraventricular tachycardias (encainide 86 patients, flecainide 369 patients) or ventricular arrhythmias (encainide 21 patients, flecainide 103 patients) to assess the frequency of proarrhythmia, cardiac arrest and death during therapy (adverse events). The two drugs were similar in regard to efficacy (flecainide 71.4%, encainide 59.8%) and rate of proarrhythmic responses (flecainide 7.4%; encainide 7.5%). However, patients receiving encainide more frequently experienced cardiac arrest (encainide 7.5% vs. flecainide 2.3%, p less than 0.05) or died during treatment (encainide 7.5% vs. flecainide 2.1%, p less than 0.05). Detailed data were provided for 44 patients experiencing one or more adverse events. Patient age, previous drug trials, concomitant therapy and days of inpatient monitoring were similar for patients receiving encainide or flecainide. However, echocardiographic left ventricular shortening before treatment was lower among patients receiving encainide (0.23 +/- 0.09) than among those receiving flecainide (0.34 +/- 0.06, p less than 0.05). Plasma drug concentrations were rarely elevated. Cardiac arrest (12 patients) and deaths (13 patients) occurred predominantly among patients with underlying heart disease, particularly among patients receiving flecainide for supraventricular tachycardia (8.3% vs. 0.3%, p less than 0.001). Fifteen patients with an ostensibly normal heart and normal ventricular function experienced proarrhythmia during treatment for supraventricular tachycardia, but only 3 of the 15 had a cardiac arrest or died. The relatively high incidence of adverse events should be considered when contemplating treatment with encainide or flecainide, particularly among patients with underlying heart disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/0735-1097(91)90586-x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210629 · Cited by 3,289
The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction.
Weir, M. (1990) · Cardiopulmonary Physical Therapy Journal · doi:10.1097/01823246-199001020-00009 · Cited by 1,061
Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.
Coplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 946
Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs.
Velebit, V., Podrid, P. J., Lown, B., Cohen, B. H., & Graboys, T. B. (1982) · Circulation · doi:10.1161/01.cir.65.5.886 · Cited by 629
Atrial flutter in the young: A collaborative study of 380 cases
Garson, A., Bink‐Boelkens, M. T. E., Hesslein, P. S., Hordof, A. J., Keane, J. F., Neches, W. H., & Porter, C.-B. J. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80497-6 · Cited by 347
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
Anderson, J. L., Gilbert, E. M., Alpert, B. L., Henthorn, R. W., Waldo, A. L., Bhandari, A. K., Hawkinson, R. W., & Pritchett, E. L. C. (1989) · Circulation · doi:10.1161/01.cir.80.6.1557 · Cited by 287
Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram
Morganroth, J., & Horowitz, L. N. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90509-5 · Cited by 280
Oral Flecainide Acetate for the Treatment of Ventricular Arrhythmias
Anderson, J. L., Stewart, J. R., Perry, B. A., Hamersveld, D. D. V., Johnson, T. A., Conard, G. J., Chang, S. F., Kvam, D. C., & Pitt, B. (1981) · New England Journal of Medicine · doi:10.1056/nejm198108273050901 · Cited by 222
Malignant ventricular tachyarrhythmias associated with the use of encainide
Winkle, R. A., Mason, J. W., Griffin, J. C., & Ross, D. L. (1981) · American Heart Journal · doi:10.1016/0002-8703(81)90036-3 · Cited by 212
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter
Gelder, I. C. V., Crijns, H. J. G. M., van Gilst, W. H., van Wijk, L. M., Hamer, H. P. M., & Lie, K. I. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90574-2 · Cited by 187
Flecainide-Induced Ventricular Tachycardia and Fibrillation in Patients Treated for Atrial Fibrillation
Falk, R. H. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-2-107 · Cited by 183
Total Suppression of Ventricular Arrhythmias by Encainide
Roden, D. M., Reele, S. B., Higgins, S. B., Mayol, R. F., Gammans, R. E., Oates, J. A., & Woosley, R. L. (1980) · New England Journal of Medicine · doi:10.1056/nejm198004173021601 · Cited by 175
Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: Identification of drugs that exacerbate tachycardia and potential mechanisms
Rinkenberger, R. L., Prystowsky, E. N., Jackman, W. M., Naccarelli, G. V., Heger, J. J., & Zipes, D. P. (1982) · American Heart Journal · doi:10.1016/0002-8703(82)90490-2 · Cited by 143
Risk factors for the development of proarrhythmic events
Morganroth, J. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90199-8 · Cited by 138
Arrhythmogenic effects of antiarrhythmic drugs: A study of 506 patients treated for ventricular tachycardia or fibrillation
Stanton, M. S., Prystowsky, E. N., Fineberg, N. S., Miles, W. M., Zipes, D. P., & Heger, J. J. (1989) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(89)90074-0 · Cited by 136
Flecainide acetate for resistant arrhythmias in the young: Efficacy and pharmacokinetics
Perry, J. C., McQuinn, R. L., Smith, R. T., Gothing, C., Fredell, P. A., & Garson, A. (1989) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(89)90070-3 · Cited by 101
Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests, and radionuclide cineangiographic studies.
DiBianco, R., Fletcher, R. D., Cohen, A. I., Gottdiener, J. S., Singh, S., Katz, R. J., Bates, H. R., & Sauerbrunn, B. J. L. (1982) · Circulation · doi:10.1161/01.cir.65.6.1134 · Cited by 100
Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation
Berns, E., Rinkenberger, R. L., Jeang, M. K., DOUGHERTY, A. H., Jenkins, M., & Naccarelli, G. V. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90915-5 · Cited by 92
The cardiac arrhythmia suppression trial: Background, interim results and implications
Pratt, C. M., & Moyé, L. A. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)91287-g · Cited by 85
Life-Threatening Flecainide Toxicity
Winkelmann, B. R., & LEINBERGER, H. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-6-807 · Cited by 73
Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: A probable proarrhythmic effect
ANASTASIOU‐NANA, M. I., Anderson, J. L., Stewart, J. R., Crevey, B. J., Yanowitz, F. G., Lutz, J. R., & Johnson, T. A. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90914-8 · Cited by 67
Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome.
Prystowsky, E. N., Klein, G. J., Rinkenberger, R. L., Heger, J. J., Naccarelli, G. V., & Zipes, D. P. (1984) · Circulation · doi:10.1161/01.cir.69.2.278 · Cited by 57
Encainide for refractory ventricular tachyarrhythmia
Chesnie, B. M., Podrid, P. J., Lown, B., & Raeder, E. A. (1983) · The American Journal of Cardiology · doi:10.1016/0002-9149(83)90014-0 · Cited by 54
The response of paediatric arrhythmias to intravenous and oral flecainide.
Wren, C., & Campbell, R. W. (1987) · Heart · doi:10.1136/hrt.57.2.171 · Cited by 48
Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics.
Till, J. A., Shinebourne, E. A., Rowland, E., Ward, D. E., Bhamra, R. K., Hågå, P., Johnston, A. E., & Holt, D. W. (1989) · Heart · doi:10.1136/hrt.62.2.133 · Cited by 46
Safety of encainide for the treatment of ventricular arrhythmias
Soyka, L. F. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90111-6 · Cited by 46
Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome
Ward, D. E., Jones, S., & Shinebourne, E. A. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90614-4 · Cited by 42
Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia
Kück, K., Kunze, K.-P., Schlüter, M., & Duckeck, W. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90014-8 · Cited by 39
Short- and long-term experience with flecainide acetate in the management of refractory life-threatening ventricular arrhythmias
Lal, R., Chapman, P. D., Naccarelli, G. V., Troup, P. J., Rinkenberger, R. L., DOUGHERTY, A. H., & Ruffy, R. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80481-2 · Cited by 38
Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
Barbey, J. T., Thompson, K. A., Echt, D. S., Woosley, R. L., & Roden, D. M. (1988) · Circulation · doi:10.1161/01.cir.77.2.380 · Cited by 35
Treatment of life-threatening ventricular tachycardia with encainide hydrochloride in patients with left ventricular dysfunction
(1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90657-1 · Cited by 29
Treatment of refractory supraventricular arrhythmias with flecainide acetate.
Till, J. A., Rowland, E., Shinebourne, E. A., & Ward, D. E. (1987) · Archives of Disease in Childhood · doi:10.1136/adc.62.3.247 · Cited by 28
Flecainide for supraventricular and ventricular arrhythmias in children and young adults
Zeigler, V. L., Gillette, P. C., Ross, B. A., & Ewing, L. L. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)91232-5 · Cited by 27
Encainide for refractory supraventricular tachycardia in children
Strasburger, J. F., Moak, J. P., Smith, R. T., McVey, P., Armstrong, K., & Garson, A. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90104-9 · Cited by 24
Electrophysiologic effects and clinical efficacy of flecainide in children with recurrent paroxysmal supraventricular tachycardia
Musto, B., D’Onofrio, A., Cavallaro, G., Musto, A., & Greco, R. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90217-2 · Cited by 22
Flecainide acetate in the treatment of resistant supraventricular arrhythmias.
Epstein, M. R., Rm, J., & Obel, I. W. P. (1988) · PubMed · Cited by 12
Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: A two-year follow-up
Facchini, M., Varisco, T., Bonazzi, O., Priori, S. G., Songa, V., & Schwartz, P. J. (1989) · American Heart Journal · doi:10.1016/0002-8703(89)90404-3 · Cited by 7

Sorted by citations

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A. M., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 3,145
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Myerburg, R. J., Quiñones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,975
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
Al‐Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T. M., Field, M. E., Fonarow, G. C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.054 · Cited by 1,902
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178233 · Cited by 1,080
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.017 · Cited by 933

See all 193

Authors: Fish, F. A., Gillette, P. C., & Benson, D. W.
Affiliations: Northwestern University (US)
Medical University of South Carolina (US)
Corresponding author: Fish, Frank A
ORCID: Fish, Frank A
Benson, D.Woodrow
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 1991-08
Volume: 18
Issue: 2
Pages: 356-365
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/0735-1097(91)90586-x
OpenAlex: W2084942160
Cited by: 193
References: 37
Citations by year: 2026: 3 · 2025: 2 · 2024: 2 · 2023: 6 · 2022: 3 · 2021: 9 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 14 · 2016: 3 · 2015: 8 · 2014: 13 · 2013: 8 · 2012: 7
FWCI: 6.21
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 8020 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: encainide, flecainide, class Ic antiarrhythmic drugs, drug-induced arrhythmia, cardiac arrest, drug-induced death, young patients, supraventricular tachycardia, ventricular arrhythmias, underlying heart disease, left ventricular shortening, adverse drug reactions, sodium channel blockers, plasma drug concentration, inpatient monitoring, drug safety and efficacy
MeSH terms: Anilides, Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Child, Death, Sudden, Flecainide, Heart Arrest, Humans, Retrospective Studies, Risk Factors, Tachycardia, Tachycardia, Supraventricular, Incidence, Encainide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks